Find your next paid study

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

~$10 – $7,500

Phase 2

Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors

This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

UNC Lineberger Comprehensive Cancer CenterNCT07630168

~$10 – $6,250

Non-small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNSCLC+3 more

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in comb…

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06343402

Tumor SkinMetastatic MelanomaMelanoma+4 more

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Obsidian Therapeutics, Inc.NCT06060613

Phase 2

A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Non-Small Cell Lung CancerMetastatic Lung Cancer

University of ChicagoNCT07603856

~$10 – $6,250

Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more

An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cel…

Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148

Phase 2

A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only an…

Metastatic CancerMetastatic Lung CancerMetastatic Breast Cancer+5 more